Published in Crit Care Med on February 01, 2003
Melioidosis: epidemiology, pathophysiology, and management. Clin Microbiol Rev (2005) 14.71
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis (2013) 5.00
Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol (2013) 4.38
Pathophysiology of sepsis. Am J Pathol (2007) 3.19
Sepsis: multiple abnormalities, heterogeneous responses, and evolving understanding. Physiol Rev (2013) 1.72
Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. Crit Care Med (2009) 1.47
Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. Proc Natl Acad Sci U S A (2009) 1.35
Animal models of sepsis. Virulence (2013) 1.22
Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care (2011) 1.17
The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer? Virulence (2013) 1.15
Sepsis-induced immune dysfunction: can immune therapies reduce mortality? J Clin Invest (2016) 1.02
Mechanisms of sepsis and insights from clinical trials. Drug Discov Today Dis Mech (2007) 0.96
Relationship of granulocyte colony stimulating factor with other acute phase reactants in man. Clin Exp Immunol (2005) 0.95
Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis. Crit Care (2005) 0.93
A biomimetic membrane device that modulates the excessive inflammatory response to sepsis. PLoS One (2011) 0.90
Therapeutic exercise attenuates neutrophilic lung injury and skeletal muscle wasting. Sci Transl Med (2015) 0.90
[Diagnosis and therapy of sepsis]. Clin Res Cardiol (2006) 0.87
Dependence of positive effects of granulocyte colony-stimulating factor on the antibiotic regimen: evaluation in rats with polymicrobial peritonitis. World J Surg (2004) 0.85
Sepsis and septic shock. Nat Rev Dis Prim (2016) 0.85
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol (2014) 0.84
Mobilisation of hematopoietic CD34+ precursor cells in patients with acute stroke is safe--results of an open-labeled non randomized phase I/II trial. PLoS One (2011) 0.83
Granulocyte colony-stimulating factor and an in vitro whole blood model of melioidosis. Eur J Clin Microbiol Infect Dis (2004) 0.82
Bench-to-bedside review: Developmental influences on the mechanisms, treatment and outcomes of cardiovascular dysfunction in neonatal versus adult sepsis. Crit Care (2007) 0.82
Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis. BMC Infect Dis (2004) 0.81
Blockade of ICAM-1 improves the outcome of polymicrobial sepsis via modulating neutrophil migration and reversing immunosuppression. Mediators Inflamm (2014) 0.78
Ethical problems of evaluating a new treatment for melioidosis. BMJ (2003) 0.78
The immune system's role in sepsis progression, resolution, and long-term outcome. Immunol Rev (2016) 0.78
Differential effects of antibiotics in combination with G-CSF on survival and polymorphonuclear granulocyte cell functions in septic rats. BMC Infect Dis (2008) 0.77
Balancing Innate Immunity and Inflammatory State via Modulation of Neutrophil Function: A Novel Strategy to Fight Sepsis. J Immunol Res (2015) 0.77
Low-dose cyclophosphamide improves survival in a murine treatment model of sepsis. Shock (2015) 0.77
Granulocyte colony-stimulating factor for severe pneumonia: what do we do when the best laid plans for men (and mice and rats...) fail? Crit Care Med (2003) 0.77
Heparin binding protein in patients with acute respiratory failure treated with granulocyte colony-stimulating factor (filgrastim)--a prospective, placebo-controlled, double-blind study. BMC Infect Dis (2013) 0.75
Sepsis Reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based model. J Theor Biol (2017) 0.75
Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med (2013) 39.56
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med (2008) 31.57
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med (2003) 28.68
Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis (2007) 24.91
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med (2004) 24.47
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med (2013) 17.37
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med (2003) 10.39
Mortality after surgery in Europe: a 7 day cohort study. Lancet (2012) 9.96
Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med (2010) 8.58
Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med (2007) 8.33
Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med (2005) 6.37
Persistent microcirculatory alterations are associated with organ failure and death in patients with septic shock. Crit Care Med (2004) 5.90
Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med (2002) 5.84
Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA (2010) 5.80
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest (2003) 5.64
Transfusion requirements in surgical oncology patients: a prospective, randomized controlled trial. Anesthesiology (2015) 5.52
Circulatory shock. N Engl J Med (2013) 4.95
Sepsis biomarkers: a review. Crit Care (2010) 4.76
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Intensive Care Med (2004) 4.56
Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol (2003) 4.45
Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis (2012) 4.07
Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med (2003) 4.04
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Early changes in organ function predict eventual survival in severe sepsis. Crit Care Med (2005) 3.97
An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis (2003) 3.93
Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care (2013) 3.90
Pulse pressure variations to predict fluid responsiveness: influence of tidal volume. Intensive Care Med (2005) 3.81
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA (2013) 3.78
Management of bleeding and coagulopathy following major trauma: an updated European guideline. Crit Care (2013) 3.65
Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med (2002) 3.63
High tidal volume and positive fluid balance are associated with worse outcome in acute lung injury. Chest (2005) 3.58
A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive Care Med (2014) 3.56
The effects of dobutamine on microcirculatory alterations in patients with septic shock are independent of its systemic effects. Crit Care Med (2006) 3.53
Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med (2004) 3.49
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care (2009) 3.48
Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med (2011) 3.34
The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med (2012) 3.18
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med (2003) 3.18
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*. Crit Care Med (2014) 3.17
Management of bleeding following major trauma: an updated European guideline. Crit Care (2010) 3.09
Microvascular response to red blood cell transfusion in patients with severe sepsis. Crit Care Med (2007) 3.06
Microbial aetiology of healthcare associated pneumonia in Spain: a prospective, multicentre, case-control study. Thorax (2013) 3.05
C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest (2003) 2.95
Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med (2007) 2.94
Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest (2008) 2.90
Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients*. Crit Care Med (2014) 2.86
Let us use the pulmonary artery catheter correctly and only when we need it. Crit Care Med (2005) 2.83
Results of the CONTROL trial: efficacy and safety of recombinant activated Factor VII in the management of refractory traumatic hemorrhage. J Trauma (2010) 2.82
Albumin administration improves organ function in critically ill hypoalbuminemic patients: A prospective, randomized, controlled, pilot study. Crit Care Med (2006) 2.74
Do all nonsurvivors of cardiogenic shock die with a low cardiac index? Chest (2003) 2.73
Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med (2005) 2.73
Microcirculatory alterations in patients with severe sepsis: impact of time of assessment and relationship with outcome. Crit Care Med (2013) 2.72
Evaluation of sublingual and gut mucosal microcirculation in sepsis: a quantitative analysis. Crit Care Med (2009) 2.68
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Sources of variability on the estimate of treatment effect in the PROWESS trial: implications for the design and conduct of future studies in severe sepsis. Crit Care Med (2004) 2.48
Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med (2006) 2.47
Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock. Crit Care Med (2007) 2.44
Patients with New York Heart Association class III heart failure may benefit with high flow nasal cannula supportive therapy: high flow nasal cannula in heart failure. J Crit Care (2013) 2.43
Sublingual capnometry tracks microcirculatory changes in septic patients. Intensive Care Med (2006) 2.40
Ethics and end-of-life care for adults in the intensive care unit. Lancet (2010) 2.40
Management of bleeding following major trauma: a European guideline. Crit Care (2007) 2.40
Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med (2012) 2.39
Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med (2004) 2.33
Severe sepsis in cirrhosis. Hepatology (2009) 2.33
Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest (2003) 2.31
A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med (2010) 2.31
Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med (2004) 2.30
Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med (2010) 2.29
Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med (2008) 2.27
The prognostic value of muscle StO2 in septic patients. Intensive Care Med (2007) 2.25
Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med (2003) 2.23
Effects of delayed oxygenation assessment on time to antibiotic delivery and mortality in patients with severe community-acquired pneumonia. Crit Care Med (2007) 2.22
Gamma-globulin levels in patients with community-acquired septic shock. Shock (2009) 2.21
Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis (2004) 2.17
A large-bolus injection, but not continuous infusion of sodium selenite improves outcome in peritonitis. Shock (2009) 2.17
Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: a matched cohort study. Crit Care Med (2003) 2.13
The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Haematologica (2006) 2.13
Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care (2010) 2.11
Diabetes does not alter mortality or hemostatic and inflammatory responses in patients with severe sepsis. Crit Care Med (2010) 2.11
Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion (2009) 2.11
Randomized, controlled clinical trials in sepsis: has methodological quality improved over time? Crit Care Med (2002) 2.10
A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med (2007) 2.08
Alcohol, immunosuppression, and the lung. Proc Am Thorac Soc (2005) 2.08
The Surviving Sepsis Campaign: raising awareness to reduce mortality. Crit Care (2003) 2.07
Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*. Crit Care Med (2012) 2.06
A clinical algorithm to diagnose invasive pulmonary aspergillosis in critically ill patients. Am J Respir Crit Care Med (2012) 2.06
Effects of fluids on microvascular perfusion in patients with severe sepsis. Intensive Care Med (2010) 2.05
Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med (2003) 2.05
Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med (2003) 2.01
An evaluation of systemic inflammatory response syndrome signs in the Sepsis Occurrence In Acutely Ill Patients (SOAP) study. Intensive Care Med (2006) 2.00
Multicenter, randomized, controlled trials evaluating mortality in intensive care: doomed to fail? Crit Care Med (2008) 2.00
Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med (2004) 1.96
Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res (2009) 1.95
Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth. Mol Cancer Res (2008) 1.94
Acinetobacter baumannii: a threat for the ICU? Intensive Care Med (2003) 1.93
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care (2011) 1.91
Retracted Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia. Oncogene (2005) 1.91
Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis (2003) 1.90